{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:29:47Z","timestamp":1784672987192,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00345-020-03392-9","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:06:33Z","timestamp":1596456393000},"page":"1897-1902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["PSA-based machine learning model improves prostate cancer risk stratification in a screening population"],"prefix":"10.1007","volume":"39","author":[{"given":"Marlon","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Mirchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Breemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Effeindzourou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Swindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"3392_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3392_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.prnil.2016.09.002","volume":"4","author":"S Cabarkapa","year":"2016","unstructured":"Cabarkapa S, Perera M, McGrath S, Lawrentschuk N (2016) Prostate cancer screening with prostate-specific antigen: a guide to the guidelines. Prostate Int 4:125\u2013129","journal-title":"Prostate Int"},{"key":"3392_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, Mansson M et al (2019) A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol 76:43\u201351","journal-title":"Eur Urol"},{"issue":"123","key":"3392_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"15","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF, Prorok PC, Yu K et al (2017) Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 15(123):592\u2013599","journal-title":"Cancer"},{"key":"3392_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00345-016-1960-x","volume":"35","author":"L Toner","year":"2017","unstructured":"Toner L, Papa N, Perera M et al (2017) Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens. World J Urol 35:935\u2013941","journal-title":"World J Urol"},{"issue":"389","key":"3392_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"25","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 25(389):815\u2013822","journal-title":"Lancet"},{"issue":"379","key":"3392_CR7","first-page":"589","volume":"9","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Emberton M, Moore CM (2018) MRI-targeted biopsy for prostate-cancer diagnosis. N Engl J Med 9(379):589\u2013590","journal-title":"N Engl J Med"},{"key":"3392_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0090-4295(02)02427-5","volume":"61","author":"K Ito","year":"2003","unstructured":"Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H (2003) Free\/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng\/mL. Urology 61:760\u2013764","journal-title":"Urology"},{"key":"3392_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1756287213513488","volume":"6","author":"S Loeb","year":"2014","unstructured":"Loeb S, Catalona WJ (2014) The prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 6:74\u201377","journal-title":"Ther Adv Urol"},{"key":"3392_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.prnil.2019.01.001","volume":"7","author":"S Nitta","year":"2019","unstructured":"Nitta S, Tsutsumi M, Sakka S et al (2019) Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity. Prostate Int 7:114\u2013118","journal-title":"Prostate Int"},{"key":"3392_CR11","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0022-5347(17)32416-3","volume":"152","author":"PB Snow","year":"1994","unstructured":"Snow PB, Smith DS, Catalona WJ (1994) Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 152:1923\u20131926","journal-title":"J Urol"},{"key":"3392_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00345-006-0132-9","volume":"25","author":"C Stephan","year":"2007","unstructured":"Stephan C, Xu C, Cammann H et al (2007) Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2\u201310 ng\/ml in 4,480 men. World J Urol 25:95\u2013103","journal-title":"World J Urol"},{"key":"3392_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.urology.2007.04.004","volume":"70","author":"C Stephan","year":"2007","unstructured":"Stephan C, Xu C, Finne P et al (2007) Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. Urology 70:596\u2013601","journal-title":"Urology"},{"key":"3392_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.294.1.66","volume":"294","author":"IM Thompson","year":"2005","unstructured":"Thompson IM, Ankerst DP, Chi C et al (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng\/ml or lower. JAMA 294:66\u201370","journal-title":"JAMA"},{"key":"3392_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-019-0193-3","volume":"16","author":"SL Goldenberg","year":"2019","unstructured":"Goldenberg SL, Nir G, Salcudean SE (2019) A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol 16:391\u2013403","journal-title":"Nat Rev Urol"},{"key":"3392_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bju.12318","volume":"112","author":"HB Carter","year":"2013","unstructured":"Carter HB (2013) American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int 112:543\u2013547","journal-title":"BJU Int"},{"issue":"319","key":"3392_CR17","first-page":"1901","volume":"8","author":"DC Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK et al (2018) Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 8(319):1901\u20131913","journal-title":"JAMA"},{"key":"3392_CR18","unstructured":"Australia PCF. PSA testing and early management of test-detected prostate cancer. 2019. cited https:\/\/www.prostate.org.au\/media\/612113\/PSA-Testing-Guidelines.pdf"},{"key":"3392_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.prnil.2016.07.002","volume":"4","author":"S McGrath","year":"2016","unstructured":"McGrath S, Christidis D, Perera M et al (2016) Prostate cancer biomarkers: are we hitting the mark? Prostate Int 4:130\u2013135","journal-title":"Prostate Int"},{"key":"3392_CR20","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.juro.2012.11.149","volume":"189","author":"S Loeb","year":"2013","unstructured":"Loeb S, Sokoll LJ, Broyles DL et al (2013) Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 189:1702\u20131706","journal-title":"J Urol"},{"key":"3392_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstrom","year":"2015","unstructured":"Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M (2015) Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68:139\u2013146","journal-title":"Eur Urol"},{"key":"3392_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.eururo.2006.07.021","volume":"51","author":"FK Chun","year":"2007","unstructured":"Chun FK, Graefen M, Briganti A et al (2007) Initial biopsy outcome prediction\u2013head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol. 51:1236\u20131240","journal-title":"Eur Urol."},{"issue":"3","key":"3392_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41747-019-0109-2","volume":"7","author":"R Cuocolo","year":"2019","unstructured":"Cuocolo R, Cipullo MB, Stanzione A et al (2019) Machine learning applications in prostate cancer magnetic resonance imaging. Eur Radiol Exp 7(3):35","journal-title":"Eur Radiol Exp"},{"issue":"9","key":"3392_CR24","doi-asserted-by":"publisher","first-page":"19518","DOI":"10.1038\/s41598-019-55972-4","volume":"20","author":"S Yoo","year":"2019","unstructured":"Yoo S, Gujrathi I, Haider MA, Khalvati F (2019) Prostate cancer detection using deep convolutional neural networks. Sci Rep 20(9):19518","journal-title":"Sci Rep"},{"key":"3392_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","volume":"36","author":"J Corfield","year":"2018","unstructured":"Corfield J, Perera M, Bolton D, Lawrentschuk N (2018) (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519\u2013527","journal-title":"World J Urol"},{"key":"3392_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403\u2013417","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03392-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:32:18Z","timestamp":1627947138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03392-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03392-9","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RM, GB, AE are employees of Maxwell Plus. LS, PS and ES hold financial interests in Maxwell Plus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}